Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about ...

Structure Therapeutics Inc. (NASDAQ: GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have ...

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...

A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but ...

As of Tuesday, January 13, Structure Therapeutics Inc.’s GPCR share price has surged by 6.29%, which has investors ...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...